However, RAAS inhibitors could benefit patients with COVID-19 through their effects on the angiotensin II expression and subsequent increases in Ang-(1–7) and (1–9), which have vasodilatory and anti-inflammatory effects that might attenuate lung injury, myocardial injury, and injury to other organs (Ingelfinger, 2009; Fraga-Silva et al., 2012; Verdecchia et al., 2012; Santos et al., 2013; Arendse et al., 2019). This evidence concerns the gene AGT and COVID-19.